Endocrine Abstracts

Background: Carcinoid syndrome (CS), the most common functional neuroendocrine tumor (NET) syndrome, is characterized by watery diarrhea or cutaneous flushing. While somatostatin receptor ligand (SRL) depot injections are mainstay treatments for CS, discomfort with injections and inadequate symptom relief at labeled doses are seen with many patients. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS...